» Articles » PMID: 29066622

MicroRNA-155 Induction Via TNF-α and IFN-γ Suppresses Expression of Programmed Death Ligand-1 (PD-L1) in Human Primary Cells

Overview
Journal J Biol Chem
Specialty Biochemistry
Date 2017 Oct 26
PMID 29066622
Citations 80
Authors
Affiliations
Soon will be listed here.
Abstract

Programmed death ligand-1 (PD-L1) is a critical regulator of T cell function contributing to peripheral immune tolerance. Although it has been shown that posttranscriptional regulatory mechanisms control PD-L1 expression in cancer, it remains unknown whether such regulatory loops operate also in non-transformed cells. Here we studied PD-L1 expression in human dermal lymphatic endothelial cells (HDLECs), which play key roles in immunity and cancer. Treatment of HDLECs with the pro-inflammatory cytokines IFN-γ and TNF-α synergistically up-regulated PD-L1 expression. IFN-γ and TNF-α also affected expression of several microRNAs (miRNAs) that have the potential to suppress PD-L1 expression. The most highly up-regulated miRNA following IFN-γ and TNF-α treatment in HDLECs was miR-155, which has a central role in the immune system and cancer. Induction of miR-155 was driven by TNF-α, the effect of which was significantly enhanced by IFN-γ. The PD-L1 3'-UTR contains two functional miR-155-binding sites. Endogenous miR-155 controlled the kinetics and maximal levels of PD-L1 induction upon IFN-γ and TNF-α treatments. We obtained similar findings in dermal fibroblasts, demonstrating that the IFN-γ/TNF-α/miR-155/PD-L1 pathway is not restricted to HDLECs. These results reveal miR-155 as a critical component of an inflammation-induced regulatory loop controlling PD-L1 expression in primary cells.

Citing Articles

The role of miR-155 in cardiovascular diseases: Potential diagnostic and therapeutic targets.

Zhang R, Wang W, Li J, Li R, Zhang J, Wu Y Int J Cardiol Cardiovasc Risk Prev. 2025; 24:200355.

PMID: 39760132 PMC: 11699627. DOI: 10.1016/j.ijcrp.2024.200355.


17β-Estradiol Abrogates TNF-α-Induced Human Brain Vascular Pericyte Migration by Downregulating miR-638 via ER-β.

Kurmann L, Azzarito G, Leeners B, Rosselli M, Dubey R Int J Mol Sci. 2024; 25(21).

PMID: 39518968 PMC: 11547073. DOI: 10.3390/ijms252111416.


Construction of circRNA-miRNA-mRNA ceRNA regulatory network and screening of diagnostic targets for tuberculosis.

Pu X, Sheng S, Fu Y, Yang Y, Xu G Ann Med. 2024; 56(1):2416604.

PMID: 39435612 PMC: 11497567. DOI: 10.1080/07853890.2024.2416604.


Translational modeling-based evidence for enhanced efficacy of standard-of-care drugs in combination with anti-microRNA-155 in non-small-cell lung cancer.

Dogra P, Shinglot V, Ruiz-Ramirez J, Cave J, Butner J, Schiavone C Mol Cancer. 2024; 23(1):156.

PMID: 39095771 PMC: 11295620. DOI: 10.1186/s12943-024-02060-5.


Regulatory mechanisms of PD-1/PD-L1 in cancers.

Lin X, Kang K, Chen P, Zeng Z, Li G, Xiong W Mol Cancer. 2024; 23(1):108.

PMID: 38762484 PMC: 11102195. DOI: 10.1186/s12943-024-02023-w.


References
1.
Herbst R, Soria J, Kowanetz M, Fine G, Hamid O, Gordon M . Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature. 2014; 515(7528):563-7. PMC: 4836193. DOI: 10.1038/nature14011. View

2.
Loke P, Allison J . PD-L1 and PD-L2 are differentially regulated by Th1 and Th2 cells. Proc Natl Acad Sci U S A. 2003; 100(9):5336-41. PMC: 154346. DOI: 10.1073/pnas.0931259100. View

3.
Yanaihara N, Caplen N, Bowman E, Seike M, Kumamoto K, Yi M . Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. Cancer Cell. 2006; 9(3):189-98. DOI: 10.1016/j.ccr.2006.01.025. View

4.
Taganov K, Boldin M, Chang K, Baltimore D . NF-kappaB-dependent induction of microRNA miR-146, an inhibitor targeted to signaling proteins of innate immune responses. Proc Natl Acad Sci U S A. 2006; 103(33):12481-6. PMC: 1567904. DOI: 10.1073/pnas.0605298103. View

5.
Vigorito E, Perks K, Abreu-Goodger C, Bunting S, Xiang Z, Kohlhaas S . microRNA-155 regulates the generation of immunoglobulin class-switched plasma cells. Immunity. 2007; 27(6):847-59. PMC: 4135426. DOI: 10.1016/j.immuni.2007.10.009. View